Skip to content
TrialScanner

NCT04649112

Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Phase 1CompletedDTILLead

Registry record

Lead sponsor
Precision BioSciences, Inc.
Conditions
CD19 Expressing Malignancies; Hematologic Malignancy
Primary completion
Dec 22, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04649112 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.